

Press Release

Utrecht, the Netherlands – AQTIS Medical™ BV, is proud to announce that the Ellansé™ dermal filler Family has received market approval for Australia. This milestone represents a major step forward in the geographical coverage of the product line, and is expected to have an additional impact on the company's growth.

The Australian aesthetics market is one of the larger markets in Asia Pacific. This market approval provides access to the Ellansé™ dermal filler Family for both practitioners and patients in order to experience the added value of this unique dermal filler.

AQTIS Medical™ is delighted to have received this approval and is confident that together with its local distribution partner, Device Technologies Australia (www.device.com.au), Ellansé™ will soon be a well-recognized, valued product in the region.

About AQTIS Medical™ BV

AQTIS Medical™ specializes in the research & development, manufacturing and commercialization of innovative medical devices, specifically designed for minimal invasive therapies within medical aesthetics and other selected therapeutic areas. We focus on medical devices that are used by physicians to enhance patients' quality of life and well-being. AQTIS Medical™ BV is a privately-held company based in Utrecht, the Netherlands.

For more information on AQTIS Medical™, please visit www.aqtismedical.com, or send an email to info@aqtismedical.com.

About Ellansé™

The Ellansé™ dermal filler Family developed by AQTIS Medical™ embeds proprietary STAT Technology™ that consists of a unique set of bioresorbable medical polymer and gel formulations. Ellansé™ is a *first in its class dermal filler*, and currently is the only available dermal filler that offers the unique combination of Sustained Performance, Tunable Longevity and Total Bioresorbability (STAT Technology™). The entire Ellansé™ dermal filler Family (S, M, L, E) is CE-certified and marketed in over 50 countries worldwide.

For more information on Ellansé™, please visit www.ellanse.com.